Cell-free multi-omics analysis reveals potential biomarkers in gastrointestinal cancer patients' blood

• Published in: Cell reports. Medicine Vol. 4; no. 11; p. 101281
• Main Authors: Tao, Yuhuan, Xing, Shaozhen, Zuo, Shuai, Bao, Pengfei, Jin, Yunfan, Li, Yu, Li, Mingyang, Wu, Yingchao, Chen, Shanwen, Wang, Xiaojuan, Zhu, Yumin, Feng, Ying, Zhang, Xiaohua, Wang, Xianbo, Xi, Qiaoran, Lu, Qian, Wang, Pengyuan, Lu, Zhi John
• Format: Journal Article
• Language: English
• Published: United States Elsevier 21.11.2023
• Subjects: Biomarkers, Tumor - genetics; Cell-Free Nucleic Acids - genetics; Gastrointestinal Neoplasms - diagnosis; Gastrointestinal Neoplasms - genetics; Humans; Multiomics; Neoplasm Staging; cell-free DNA; multi-omics; cancer diagnosis; cell-free RNA; liquid biopsy
• ISSN: 2666-3791; 2666-3791
• DOI: 10.1016/j.xcrm.2023.101281

During cancer progression, tumorigenic and immune signals are spread through circulating molecules, such as cell-free DNA (cfDNA) and cell-free RNA (cfRNA) in the blood. So far, they have not been comprehensively investigated in gastrointestinal cancers. Here, we profile 4 categories of cell-free omics data from patients with colorectal cancer and patients with stomach adenocarcinoma and then assay 15 types of genomic, epigenomic, and transcriptomic variations. We find that multi-omics data are more appropriate for detection of cancer genes compared with single-omics data. In particular, cfRNAs are more sensitive and informative than cfDNAs in terms of detection rate, enriched functional pathways, etc. Moreover, we identify several peripheral immune signatures that are suppressed in patients with cancer. Specifically, we establish a γδ-T cell score and a cancer-associated-fibroblast (CAF) score, providing insights into clinical statuses like cancer stage and survival. Overall, we reveal a cell-free multi-molecular landscape that is useful for blood monitoring in personalized cancer treatment.